• DOI:10.1056/NEJMoa050493
Corpus ID: 8161299

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

@article{Bresalier2005CardiovascularEA,
  title={Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.},
  author={R. Bresalier and R. Sandler and H. Quan and J. Bolognese and Bettina Oxenius and K. Horgan and C. Lines and R. Riddell and D. Morton and {\'A}. Lanas and M. Konstam and J. Baron},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 11},
  pages={
          1092-102
        }
}

R. Bresalier, R. Sandler, +9 authors J. Baron

Published 2005

Medicine

The New England journal of medicine

BACKGROUND Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of… CONTINUE READING

View PDF

Save to Library

Create Alert

Cite

Launch Research Feed